News
The latest insights, sector developments and case updates from Potter Clarkson. Explore up-to-date content from our experts and stay informed on the issues shaping the IP landscape.
The latest insights, sector developments and case updates from Potter Clarkson. Explore up-to-date content from our experts and stay informed on the issues shaping the IP landscape.

As 2025 draws to a close, brand owners face an important deadline that could affect their UK trade mark rights. From 1 January 2026, it is no longer possible to rely on evidence of use in the EU to maintain the validity of UK comparable trade marks (often called “Brexit clones”). This marks the end of the grace period for use, originally set out in the UK/EU Withdrawal Agreement.

Potter Clarkson has once again been highly recognised in the 2026 Legal 500 rankings, a leading guide for clients seeking top law firms, attorneys, and solicitors.
.avif)
Following its previous widely-reported ruling earlier this year, the Mannheim Local Division has now issued its decision in respect of the UK aspect of the infringement proceedings brought by FujiFilm, marking the first time that the UPC has granted an injunction which applies to the UK.

Space agriculture (or as you may know it, space-based AgTech, astroagriculture, exo-agriculture, off-earth farming or extraterrestrial food systems) refers to agricultural technologies and systems developed or tested in space.

From engineered microbes cleaning up environmental waste to CRISPR-edited cells powering next-generation therapies, synthetic biology is shaping industries, economies, and everyday life.

The SPC manufacturing waiver, introduced in 2019 under Regulation (EU) No 2019/933, marked a pivotal development in EU pharmaceutical law.

Gene editing technologies like CRISPR and RNA interference (RNAi) are revolutionising agriculture.

A Board of Appeal at the EPO has referred questions to the Enlarged Board of Appeal (EBA) in connection with inconsistencies between the claims and description of a European patent vs. those of a European patent application (pre-grant vs. post-grant).
.avif)
In the recent decision Generics v AstraZeneca, the UK Court of Appeal confirmed that the UK’s approach to ‘plausibility’ remains unchanged despite the EPO Enlarged Board of Appeal decision G2/21.
.avif)
In April 2023, the European Commission adopted a comprehensive package of proposed reforms to the legislation governing the authorisation of medicines in the EU.

The revamped UPC Case Management System (‘CMS’) is now live. The objective of the new CMS is to simplify access for users. This will be a welcome update for IP practitioners who have in the past experienced various issues when using the old CMS.
.avif)
The implementation of the Windsor Framework on 1 January 2025 marked a significant turning point in the UK’s regulatory landscape for human medicines.
.avif)
The Enlarged Board of Appeal of the European Patent Office has issued a landmark decision (G1/23) significantly altering the interpretation of what constitutes prior art.
.avif)
At a recent webinar hosted by the BioIndustry Association (BIA), speakers from DEFRA and Covington outlined the current state of play. Here are the key takeaways for companies working with DSI, and some early steps they can take.
.avif)
The Court of Appeal (CoA) confirms the UPC’s jurisdiction over infringements committed before 1 June 2023 and during an opt-out period where the European patent is subsequently opted back into the jurisdiction of the UPC.

A new report from the European Union Intellectual Property Office (EUIPO), released in June 2025, has laid bare the growing scale and sophistication of food and drink counterfeiting across Europe.